International Product List

Business Development & Licensing

2026



A focused portfolio platform for international partners

Available products, selected-market opportunities, under-development dossiers and in-process assets presented for licensing, supply and business development discussions.

10
Available & selected-market assets

6
Under-development dossiers with target availability

12
In-process molecules for strategic evaluation

Portfolio focus

- Anticoagulants
- Diabetes
- CNS
- Cardio-Renal
- MASH
- Women's Health

Pharmazac
Healthcare Innovation from **A** to **Z**

www.pharmazac.com | bd@pharmazac.com

Market-ready portfolio

Products available for focused partner discussions and selected-market opportunities.

AVAILABLE **Market-ready product opportunities**

PRODUCT	FORM	STRENGTH	THERAPEUTIC AREA
Apixaban	F.c. tablets	2.5 mg, 5 mg	Oral Anticoagulant
Linagliptin	F.c. tablets	5 mg	Oral Antidiabetic
Micafungin	Powder for solution for infusion	50 mg/10 ml, 100 mg/10 ml	Antifungal
Rivaroxaban	F.c. tablets	2.5 mg, 10 mg, 15 mg, 20 mg	Oral Anticoagulant
Sitagliptin Hydrochloride + Metformin	F.c. tablets	50 mg + 850 mg, 50 mg + 1000 mg	Oral Antidiabetic
Sitagliptin Hydrochloride	F.c. tablets	25 mg, 50 mg, 100 mg	Oral Antidiabetic
Sugammadex	Solution for injection	100 mg/ml	Reversion of the effect of rocuronium and vecuronium
Ticagrelor	F.c. tablets	60 mg, 90 mg	Platelet aggregation inhibitor

SELECTED MARKETS **Opportunities linked to specific market scope**

Product	Form	Strength	Therapeutic area
Calcium Folinate injectable	Solution for injection	200 mg / 20 ml	Detoxifying agents for antineoplastic treatment
Rosuvastatin + Ezetimibe	F.c. tablets	(5+10) mg, (10+10) mg, (20+10) mg, (40+10) mg	Treatment of high cholesterol and triglyceride levels

Under development

Pipeline products with target dossier availability for BD planning.

Development pipeline designed for practical commercial execution

Dossier availability dates are provided as planning guidance for discussions with international partners and may be further refined during project alignment.

UNDER DEVELOPMENT **Dossier availability included**

PRODUCT	FORM	STRENGTH	THERAPEUTIC AREA	DOSSIER
Bempedoic acid	F.c. Tablets	180 mg	LDL Cholesterol	Q3 2027
Bempedoic acid + Ezetimibe	F.c. Tablets	180 mg + 10 mg	LDL Cholesterol	Q3 2027
Brexpiprazole	F.c. Tablets	0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg	CNS / Antipsychotic	Q2 2028
Dapagliflozin	F.c. Tablets	5 mg, 10 mg	Oral Antidiabetic	Q4 2026
Dapagliflozin + Metformin	F.c. Tablets	5 mg + 850 mg 5 mg + 1000 mg	Oral Antidiabetic	Q4 2026
Daridoxerant	F.c. Tablets	25 mg, 50 mg	CNS / Insomnia	Q3 2028
Edoxaban	F.c. Tablets	15 mg, 30 mg, 60 mg	Oral Anticoagulant	Q1 2028
Fezolinetant	F.c. Tablets	45 mg	Women's Health	Q3 2028
Finerenone	F.c. Tablets	10 mg, 20 mg	Cardio-Renal	Q2 2028
Fosmomycin Tromethamie	Sachet	3gr.	Antibiotic	Q4 2028
Linagliptin + Metformin	F.c. Tablets	2.5/850 mg 2.5/1000 mg	Oral Antidiabetic	Q4 2027
Safinamide Mesylate	F.c. Tablets	50 mg, 100 mg	CNS / Parkinson	Q1 2027

Partner discussion points

Territory scope and exclusivity

Forecast and launch timing

Regulatory pathway and dossier package

Supply model and pricing assumptions

In process

Strategic molecules currently under evaluation for future portfolio development.



IN PROCESS

Further technical, regulatory, IP and commercial assessment required

PRODUCT	FORM	STRENGTH	THERAPEUTIC AREA
Aripiprazole tabs	F.c. tablets	TBD	CNS / Antipsychotic
Ferric carboxymaltose	Solution for injection / infusion	TBD	Iron deficiency / Anemia
Iron sucrose injection	Solution for injection / infusion	TBD	Iron deficiency / Anemia
Mavacamten	Hard capsule	2.5 mg, 5 mg, 10 mg, 15 mg	Cardiology
Resmetirom	F.c. tablets	60 mg, 80 mg, 100 mg	Hepatology / MASH
Sacubitril + Valsartan + Dapagliflozin	F.c. tablets	TBD	Cardio-Renal / Heart Failure
Vortioxetine tabs	F.c. tablets	5 mg, 10 mg, 15 mg, 20 mg	CNS / Antidepressant

Contact

Business Development & Licensing

1, A. Zaroliagki & 6, D. Lamprou Str., GR-19001 Keratea - Attica, Greece

Tel.: +30 210 341 8889 | Fax.: +30 210 866 1262

E-mail: bd@pharmazac.com | www.pharmazac.com

Licensing | Supply | Portfolio Development | International Business Development

Pharmazac

Healthcare Innovation from A to Z